Table 1: Individual study details and kidney-related outcomes.

Author/ Study Design Follow-up (years, ±SD) Group BMI (kg/m2) N GFR estimation method/
Creatinine Clearance
Nogueira [20]/
Prospective		 7.1± 1.6 Control <35 31 MDRD
Study ≥35 8
Nogueira [21]/ Prospective 6.8 ± 1.5 Study* ≥30 36 MDRD
Locke [22]/ Retrospective 10.7 median (26.8 max) Control <30 58,004 CKD-epi
Study ≥30 20,588
Bello [23]/ Cross-sectional 12.37 ± 7.60 Control <30 57 Cystatin-C based formula of Rule
Study ≥30 20
Ibrahim [24]/ Prospective 12.2 ± 9.2 Study† ≤30 180 Iohexol
>30 75
Tavakol [25]/ Prospective 11 ± 7 Control <30 82 MDRD
Study ≥30 16
Taner [26]/ Prospective 5.8 Control ≤35 16 125I-iothalamate clearance
Study >35 11
Kerkeni [27]/ Retrospective 9.28 ± 6.3 Control <25 87 Creatinine Clearance
Study 1 25–<30 62
Study 2 ≥30 40
Gracida [28]/ Prospective 6.725 ± 2.715 Control ≤30 422 Creatinine Clearance
Study >30 81

*Controls from cohort of non-obese LKDs from the study by Ibrahim et al
†Matched controls from National Health and Nutrition Examination Survey 2003-2004, 2005-2006